RWE is at the root of a critical transformation in the way we are looking at clinical development, drug life cycle and commercialization activities

Today more than ever, real-world data collected from mobile, digital and AI technologies are used to help drug developers in generating more value-based outcomes in the development and accessibility of new treatments.

To gain competitive advantage and achieve better outcomes, pharma and biotech organizations seek to advance the way they use RWE - real-world evidence, for the benefit of patients and the commercial success of their products.